ArticleWorld journal of surgical oncology2023
A combined preoperative red cell distribution width and carcinoembryonic antigen score contribute to prognosis prediction in stage I lung adenocarcinoma.
Article in World journal of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 6 citations in OpenAlex.
- Prognostic impact of CEACAM5 in nonsquamous non-small cell lung cancer: a critical reappraisal driven by cut-off optimization.Translational lung cancer research · 2026Article
- Mean Corpuscular Volume as a Prognostic Marker in Patients with Non-Small Cell Lung Cancer Undergoing Surgical Resection: A Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Development and validation of prognostic models based on cell cycle-related signatures for predicting the prognosis of patients with lung adenocarcinoma.Translational cancer research · 2025Article
- Prognostic Significance of Modified Shine and Lal Index in Patients with Non-Small Cell Lung Cancer Undergoing Surgical Resection.Biomedicines · 2025Article
- Antibiotic Usage During Surgery may be Correlated With Survival in Radically Resected Non-Small-Cell Lung Cancer Patients.Clinical Medicine Insights. Oncology · 2025Article
- Prognostic Value of Tertiary Lymphoid Structures in Stage I Nonsmall Cell Lung Cancer: Does Location Matter?Clinical Medicine Insights. Oncology · 2025Article
- Preoperative absolute neutrophil count: a potential indicator for prognosis in carcinoembryonic antigen normal stage I non-small cell lung cancer.Frontiers in oncology · 2025Article
- Sex-based differences in CEACAM5 expression in lung cancer.Translational cancer research · 2024Article
- The use of non-steroid anti-inflammatory drugs during radical resection correlated with the outcome in non-small cell lung cancer.World journal of surgical oncology · 2023Article
- Prognostic impact of highly solid component in early-stage solid lung adenocarcinoma.Quantitative imaging in medicine and surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHematological markers that can be used for prognosis prediction for stage I lung adenocarcinoma (LUAD) are still lacking. Here, we examined the prognostic value of a combination of the red cell distribution width (RDW) and carcinoembryonic antigen (CEA), namely, the RDW-CEA score (RCS), in stage I LUAD. MATERIALS AND
methodsA retrospective study with 154 patients with stage I LUAD was conducted. Patients were divided into RCS 1 (decreased RDW and CEA), RCS 2 (decreased RDW and increased CEA, increased RDW and decreased CEA), and RCS 3 (increased RDW and CEA) subgroups based on the best optimal cutoff points of RDW and CEA for overall survival (OS). The differences in other clinicopathological parameters among RCS subgroups were calculated. Disease-free survival (DFS) and OS among these groups were determined by Kaplan-Meier analysis, and risk factors for outcome were calculated by a Cox proportional hazards model.
resultsSeventy, 65, and 19 patients were assigned to the RCS 1, 2, and 3 subgroups, respectively. Patients ≥ 60 years (P < 0.001), male sex (P = 0.004), T
conclusionsRCS is a useful prognostic indicator in stage I LUAD patients, and RCS 3 patients have poorer survival. However, randomized controlled trials are needed to validate our findings in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.